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Abstract
Background: We compared Glycine Propionyl-L-Carnitine (GlycoCarn®) and three different pre-workout nutritional 
supplements on measures of skeletal muscle oxygen saturation (StO2), blood nitrate/nitrite (NOx), lactate (HLa), 
malondialdehyde (MDA), and exercise performance in men.
Methods: Using a randomized, double-blind, cross-over design, 19 resistance trained men performed tests of 
muscular power (bench press throws) and endurance (10 sets of bench press to muscular failure). A placebo, 
GlycoCarn®, or one of three dietary supplements (SUPP1, SUPP2, SUPP3) was consumed prior to exercise, with one 
week separating conditions. Blood was collected before receiving the condition and immediately after exercise. StO2 
was measured during the endurance test using Near Infrared Spectroscopy. Heart rate (HR) and rating of perceived 
exertion (RPE) were determined at the end of each set.
Results: A condition effect was noted for StO2 at the start of exercise (p = 0.02), with GlycoCarn® higher than SUPP2. A 
condition effect was also noted for StO2 at the end of exercise (p = 0.003), with SUPP1 lower than all other conditions. 
No statistically significant interaction, condition, or time effects were noted for NOx or MDA (p > 0.05); however, MDA 
decreased 13.7% with GlycoCarn® and increased in all other conditions. Only a time effect was noted for HLa (p < 
0.0001), with values increasing from pre- to post-exercise. No effects were noted for HR, RPE, or for any exercise 
performance variables (p > 0.05); however, GlycoCarn® resulted in a statistically insignificant greater total volume load 
compared to the placebo (3.3%), SUPP1 (4.2%), SUPP2 (2.5%), and SUPP3 (4.6%).
Conclusion: None of the products tested resulted in favorable changes in our chosen outcome measures, with the 
exception of GlycoCarn® in terms of higher StO2 at the start of exercise. GlycoCarn® resulted in a 13.7% decrease in MDA 
from pre- to post-exercise and yielded a non-significant but greater total volume load compared to all other 
conditions. These data indicate that 1) a single ingredient (GlycoCarn®) can provide similar practical benefit than 
finished products containing multiple ingredients, and 2) while we do not have data in relation to post-exercise 
recovery parameters, the tested products are ineffective in terms of increasing blood flow and improving acute upper 
body exercise performance.
Background
The use of nutritional supplements for sport continues to
increase [1], with athletes and recreationally active train-
ees routinely seeking methods to improve performance.
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In particular, the category of sport supplements known as
the "pre-workout" class appears to be a staple in the regi-
men of many athletes, bodybuilders and strength athletes
in particular. These products typically contain a combi-
nation of several (30+) ingredients, and usually contain
stimulants (e.g., caffeine), energy-producing agents (e.g.,
creatine), agents that act as hydrogen ion buffers (e.g.,
beta alanine), protein recovery nutrients (e.g., amino
acids), antioxidants, and nitric oxide precursors (e.g.,
arginine). In relation to the latter, an entire class of sport
supplement ("nitric oxide boosters") has been built
around the theoretical increase in nitric oxide following
intake of L-arginine, and the supposed but unsubstanti-
ated correlation between increased circulating nitric
oxide and improved exercise performance and recovery
[2]. Companies developing and selling such products
boldly claim that a single use of the product will rapidly
and dramatically increase circulating nitric oxide and
result in an improvement in blood flow, muscle "pump",
and exercise performance.
Collectively, hundreds of studies have been conducted
testing the commonly used pre-workout ingredients in
isolation, many with reported positive findings related to
the chosen outcome measures. For example, caffeine
intake prior to exercise has been reported to improve
both aerobic and anaerobic exercise performance,
although results are mixed [3,4]. The dosage used in most
studies has ranged from 3-7mg•kg-1 consumed prior to
exercise [3,4], although higher amounts have certainly
been used in many studies. Creatine is another well-stud-
ied nutrient noted to improve high intensity exercise per-
formance [5]. The traditional dosage used in most studies
is 5 grams per day, usually taken for a series of days/weeks
leading up to the exercise test protocol. One relatively
new ingredient which shows promise is beta alanine. This
agent has been reported in most [6-9], but not all studies
[10,11], to decrease lactate accumulation and/or aid in
exercise performance. The dosage used in most studies
ranges from 3-6 grams per day, usually taken for a series
of days/weeks leading up to the exercise test protocol.
The novel ingredient Glycine Propionyl-L-Carnitine
(GlycoCarn®) has been reported recently to improve
repeated sprint cycle performance and reduce the blood
lactate response to exercise when consumed in a single
dosage of 4.5 grams [12]. We have also reported an
increase in nitric oxide (measured as nitrate/nitrite) when
subjects received GlycoCarn®  at a daily dosage of 4.5
grams for either four [13] or eight [14] weeks. Lastly, sev-
eral antioxidant agents have been reported to decrease
the oxidative stress response to exercise [15], and are
believed to promote exercise recovery; hence, these are
often included within some pre-workout supplements.
While the data obtained from investigations focused on
the study of individual ingredients indeed support the use
of such ingredients when included at the correct dosages,
most finished products contain a combination of multiple
ingredients at extremely low dosages. Moreover, most of
the current pre-workout dietary supplements claim to
increase nitric oxide production, which in turn will
increase blood flow, muscle pumps, and overall exercise
performance.
Two concerns arise when considering the above claims:
1) Aside from GlycoCarn® when used at a daily dosage of
4.5 grams, there are no peer reviewed and published data
in scientific manuscript format pertaining to a dietary
supplement, consumed in oral form by healthy subjects,
to support an increase in nitric oxide; 2) Even if data were
available demonstrating an increase in blood nitric oxide
following dietary supplement intake, no evidence exists
to support the claim that increased circulating nitric
oxide leads to better muscle pumps or improved exercise
performance. Such a claim is premature and requires lab-
oratory testing in order to be substantiated. Therefore,
the purpose of the present study was to compare Glyco-
Carn®  and three different popular pre-workout "nitric
oxide stimulating" nutritional supplements on measures
o f  s k e l e t a l  m u s c l e  o x y g e n  s a t u r a t i o n  ( S t O 2), blood
nitrate/nitrite (NOx), blood lactate (HLa), malondialde-
hyde (MDA), and exercise performance in a sample of
resistance trained men. It should be understood that no
attempt was made to determine the effects of the tested
products on post-exercise recovery components. There-




Nineteen resistance trained men were recruited from the
University of Memphis and local surrounding community
and completed all aspects of this study. All men per-
formed resistance exercise a minimum of three days per
week for the past 12 months, with the majority of subjects
training more frequently and for much longer than the
past 12 months (Table 1). Subjects were not current
smokers, and did not have cardiovascular, metabolic, or
orthopedic problems that might affect their ability to per-
form submaximal and maximal resistance exercise. Sub-
ject characteristics are presented in Table 1. Health
history, drug and dietary supplement usage, and physical
activity questionnaires were completed by all subjects to
determine eligibility. Subjects were instructed to main-
tain their current training and nutritional regimen
throughout the course of the study period, with the
exception of the 48 hours prior to each test session in
which they were instructed not to perform any strenuousBloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
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exercise. The study was approved by the university com-
mittee for human subject research and all subjects pro-
vided both verbal and written consent.
Design
This study involved a randomized, placebo controlled,
cross-over, double blind design. During the first visit to
the laboratory, subjects gave written informed consent
and completed health and physical activity question-
naires. Additionally, the subjects' height, weight, and
body composition (via 7 site skinfold test) was measured.
Heart rate and blood pressure were recorded following a
10 minute period of quiet rest. Familiarization trials were
performed for the bench press throw (using a ProSpot®
device; ProSpot Fitness, Norcross, GA). A maximal test in
the bench press exercise was performed using a supine
Hammer Strength™ bench press apparatus, in order to
determine subjects' one repetition maximum (1RM).
Guidelines from the National Strength and Conditioning
Association were followed [16]. Testing began, as
described below, within one week after the completion of
this screening visit.
Conditions
Subjects underwent the exact exercise testing protocol a
total of six times, each visit separated by one week. The
conditions included a placebo powder (16 grams of
maltodextrin), Glycine Propionyl-L-Carnitine (16 grams
of maltodextrin + 4.5 grams of GlycoCarn®; Sigma-tau
HealthScience, Gaithersburg, MD), Supplement 1
(SUPP1--lot # 9084; expiration 04/2012; see Figure 1),
Supplement 2 (SUPP2--lot #62149A; expiration 06/2011;
see Figure 2), and Supplement 3 (SUPP3--lot # 907495;
expiration 09/2011; see Figure 3). Subjects were simply
told that they were receiving a "pre-workout" supple-
ment. For each of the supplements used for comparison,
two servings were provided to subjects. Sixteen grams of
maltodextrin was added to the GlycoCarn® and also used
as the placebo in an attempt to match the mean amount
of maltodextrin contained within the supplements used
in comparison (when considering our two-serving dos-
age). All conditions were mixed into 12 ounces of water
and consumed 30 minutes prior to the start of the exer-
cise test protocol, with the exception of the GlycoCarn®
condition which was consumed 60 minutes prior to the
start of exercise. The time of administration of each con-
dition was similar to the recommended time of intake
provided on the product label, while a recent study using
GlycoCarn® for performance improvement had subjects
consume this condition 90 minutes prior to exercise [12].
Our rationale for the change to 60 minutes prior to exer-
cise was based on our inclusion of maltodextrin to the
GlycoCarn® in the current design and the fact that the
added carbohydrate may have enhanced uptake of the
GlycoCarn®, as well as the fact that we wanted to maintain
as much similarity in the treatment protocol as possible.
Prior to using any of the above five conditions, all sub-
jects underwent an identical test protocol using water
only. This was to serve as a baseline familiarization trial
to the protocol, as we have previously noted that even in
well trained men, such a protocol as used in the present
design requires one session in order to fully familiarize
subjects to the exercise movements and the volume of
exercise (unpublished findings). Hence, a total of six ses-
sions of the exercise protocol were performed by all sub-
jects. It should be noted that the baseline condition,
although presented within the results section for compar-
ison purposes, was not used in the statistical analysis.
All conditions were provided in powder form and were
fruit punch flavor. The placebo and GlycoCarn® condi-
tions were produced and then packaged into individual
servings by Tishcon Corporation (Westbury, NY). The
three supplements used for comparison were purchased
from a local General Nutrition Center store in containers.
To ensure precision of dosing, each of these three condi-
tions was weighed on a laboratory grade balance prior to
mixing in water . Again, two servings of each condition
were used in this design. Our rationale for this was based
on the fact that the majority of users of such supplements
use 2-3 servings rather than one. In fact, the label instruc-
tions for use of these products indicate a serving size
between 1 and 3 servings. Unlike GlycoCarn®, which is
Table 1: Descriptive characteristics of 19 resistance trained 
men.
Variable Value
Age (yrs) 24 ± 4
Height (cm) 176 ± 5
Weight (kg) 80 ± 7
Body mass index (kg•m-2)2 6  ±  3
Body fat (%)* 13 ± 3
Waist:Hip 0.86 ± 0.04
Years resistance exercise 7 ± 4
Hours/wk resistance exercise 4 ± 2
Bench press 1-RM (kg) 150 ± 39
Resting heart rate (bpm) 65 ± 13
Resting systolic blood 
pressure (mmHg)
119 ± 11
Resting diastolic blood 
pressure (mmHg)
69 ± 8
Data are mean ± SD.
*Determined from 7-site skinfold analysis use Lange calipers and 
Siri equationBloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
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obviously a single ingredient (mixed with maltodextrin in
the present design), the supplements contained numer-
ous ingredients (as can be seen in Figures 1, 2, and 3),
some of which are stimulants.
Exercise Test Protocol
For all six test days, subjects reported to the lab following
a minimum of an eight hour overnight fast. After arrival
to the lab, a blood sample was obtained following a 10
minute period of rest. Subjects then rated their perceived
and subjective level of muscle "pump" in the upper body
using a visual analog scale (0 = no pump; 10 = the most
intense pump ever experienced). This subjective measure
was explained to subjects as an intense feeling of swell
within the muscle, in such a way that the muscle feels big-
ger, fuller, and harder. As all subjects were resistance
trained men, all had a full understanding of the described
feeling. A circumference measure of the upper torso was
also taken twice using a tension regulated tape measure
(across the nipple line with the shirt removed), and the
mean of two measures was recorded. Subjects stood
relaxed during these measures with their arms at their
sides. These exact measures for muscle pump and cir-
cumference were taken a second time, within five min-
utes of completing the exercise protocol. Subjects then
consumed their assigned condition and prepared for the
performance tests. During this time, subjects were fitted
with a heart rate monitor to be worn during the entire
exercise test protocol. Following the required time (60
minutes for GlycoCarn® and 30 minutes for all other con-
ditions), the performance tests were performed in the
order described below. No other food or calorie-contain-
ing drinks were allowed during testing, but water was
allowed ad libitum for the first session and matched for
all conditions and days of testing. Although water intake
was matched for each subject for each condition, we did
not measure hydration status of subjects. This may be
considered a limitation of the present work, as hydration
status has been reported to influence the hormonal envi-
ronment associated with acute resistance exercise [17],
which could have possibly influenced our outcome mea-
sures.




Glucose Polymer Blend, Creatine Monohydrate, NO2 Complex [L-Arginine, L-Arginine Alpha-Ketoglutarate 
(A-AKG), L-Arginine Ketoisocaproate (A-KIC)], Guanipro™ (Guanidino Propionic Acid), Salicyclic Acid 15%, 
Panax Ginseng Extract 
L-Tyrosine, Methylxanthines (Caffeine), NAC (N-Acetyl-Cysteine), N-Acetyl-Tyrosine, Glucuronolactone, 
Rhodiola Rosea Root Extract (Standardized To 5% Total Rosavins), Ginko Biloba Extract 
Taurine, L-Leucine, L-Glutamine, L-Valine, L-Isoleucine, L-Citruline AKG, Turkesterone (11,20 
Dihydroxyecdysone From Ajuga Turkestanica Extract), Choline Bitartrate 
Indole-3-Carbinol, 4-Hydroxyisoleucine (From Fenugreek Seed Extract), Cinnamon Bark Extract, Bacopa 
Monniera 
Potassium Gycerophosphate, Magnesium Glycerophosphate, Alpha Lipoic Acid, Bioperine™ 
 
Figure 2 Supplement 2 ingredients (per one serving).
Ingredients 
 
L-Arginine AKG, L-Citrulline Malate, RC-NOS™ (Rutacarpine 95%), L-Citrulline AKG, L-Histidine AKG, NAD 
(Nicotinamide Adenine Dinucleotide), Gynostemma Pentaphyllum (Leaves & Stem) (Gypenosides 95%) 
Modified Glucose Polymers (Maltodextrin), Di-Creatine Malate, Trimethylglycine, Creatine Ethyl Ester -Beta-
Alanine Dual Action Composite (CarnoSyn®), Sodium Bicarbonate, Sodium Creatine Phosphate Matrix, Creatinol-
O-Phosphate-Malic Acid Interfusion, Glycocyamine, Guanidino Proplonic Acid, Cinnulin PF® (Aqueous Cinnamon 
Extract) (Bark), Ketoisocaproate Potassium, Creatine ABB (Creatine Alpha-Amino-N-Butyrate) 
L-Tyrosine, Taurine, Glucuronolactone, Methylxanthine (Caffeine), L-Tyrosine AKG, MCT's (Medium Chain 
Triglycerides)[Coconut], Common Periwinkle Vinpocetine 99%, Vincamine 99%, Vinburnine 99% (Whole Plant) 
Di-Calcium Phosphate, Di-Potassium Phosphate, Di-Sodium Phosphate 
Potassium Glycerophosphate, Magnesium Glycerophosphate, Glycerol Stearate 
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Performance Testing
As a measure of muscular power, bench press throws
were performed using the ProSpot® device. Following a
warm-up of 10% of their predetermined 1RM, subjects
performed three throws using 30% of 1RM. Ninety sec-
onds of rest was provided between each throw. The best
attempt of the three throws was recorded and used in the
data analysis. A detailed description of this assessment is
provided elsewhere [18]; however basic procedures were
as follows. Kinetic and kinematic data were acquired
through the combination of a modified floor scale
(Roughdeck, Rice Lake Weighing Systems, Rice Lake, WI)
and a linear velocity/position transducer (VP510, Unime-
asure, Corvallis, OR). The linear transducer was mounted
superior to the barbell and was centrally tethered to the
barbell. Measurements of force and velocity were mea-
sured directly by the modified floor scale and linear
transducer, respectively. Power was calculated indirectly
via inverse dynamic equations within our acquisition
software (DataPac 5).
Following the bench press throws, a sensor was placed
on subjects' dominant arm anterior deltoid muscle for a
measure of muscle tissue oxygen saturation using Near
Infrared Spectroscopy (NIRS), as described below. Sub-
jects then performed the bench press test which involved
10 sets in the Hammer Strength™ supine bench press
exercise using a load equal to 50% of 1RM. This same
intensity of resistance exercise has been used in many
previous studies, and also used in one of the few studies
incorporating the measure of NIRS [19]. All sets of exer-
cise were performed to a point of momentary muscular
failure, with 120 seconds of rest between each set. Total
repetitions performed for each set were recorded, and
total and mean volume load (reps × load) was calculated.
Immediately at the conclusion of each set, heart rate and
perceived exertion (using the 6-20 Borg scale) were
recorded. The mean values over all 10 sets for heart rate
and perceived exertion for each test day were computed
and used in data analysis.
Near Infrared Spectroscopy (NIRS)
Muscle tissue oxygen saturation was measured continu-
ously during the bench press protocol (both work and
rest) using the InSpectra™ Tissue Oxygenation Monitor
(Hutchinson Technology; Hutchinson, MN). This system
u s e s  n e a r  i n f r a r e d  s p e c t r o s c o p y  ( N I R S ;  i . e . ,  c a l i b r a t e d
wavelengths of near infrared light) to noninvasively illu-
minate the tissue below a sensor that is placed on the skin
surface. This device provides quantification of the ratio of
oxygenated hemoglobin to total hemoglobin in the
microcirculation of the volume of illuminated tissue. The
system does this via use of a sensor attached to the sub-
jects' skin (anterior deltoid in the present design).
Through pilot testing it was determined that the system
Figure 3 Supplement 3 ingredients (per one serving).
Ingredients 
 
D-Glucose Monosaccharide, L-Arginine, Taurine, L-Aspartic Acid, Disodium Phosphate, Dipotassium Phosphate, 
Dicalcium Phosphate, Xanthinol Nicotinate, L-Arginine Ketoisocaproic Acid, L-Arginine Ethyl Ester HCL, L-
Norvaline, L-Norvaline Ethyl Ester HCL, Citrulline Malate, L-Citrulline Ethyl Ester L-Histidine Alpha-
Ketoglutarate, Gynostemma Pentaphyllum Extract (Root) (Standardized To 85% Gypenosides), Acetyl L-Carnitine 
L-Arginine Dihydrochloride, Artichoke Extract (As Cynara Scolymus L.)(Root) Standardized To 5% Chlorogenic 
Acid, Crataegus Pinnatifida Bunge Extract (Fruit) 
Maltodextrin, Creatine Monohydrate, Creatine Anhydrous, Creatine Malate, Creatine Taurinate, Creatine HCA, 
Creatine L-Pyroglutamate, Taurine Ethyl Ester HCL, Taurine Alpha-Ketoglutarate, 18 Beta Glycyrrhetinic Acid, 
Coriolus Versicolor Powder (Plant) 
Glycine, L-Leucine, L-Isoleucine, L-Valine, Beta Alanine, Beta Alanine Ethyl Ester HCL, L-Leucine Methyl Ester 
HCL, L-Leucine Alpha-Ketoglutarate, L-Leucine Isovaleric Acid, L-Isoleucine Ethyl Ester HCL, L-Isoleucine 
Methyl Ester HCL, L-Valine Ethyl Ester HCL, L-Valine Alpha-Ketoglutarate, Alpha Amino N-Butyrate 
Caffeine Anhydrous (Standardized For 117 Mg Caffeine), Yerba Mate Powder (As Llex Paraguariensis)(Leaf), N-
Acetyl-L-Carnitine HCL, Yohimbine HCL (Pausinystalia Yohimbe)(Bark), Evodia Rutaecarpa Extract (As 
Tetradium Ruticarpum)(Fruit) (Standardized For 10% Evodiamine), Black Tea Extract (As Camellia Sinensis)(Leaf) 
(Standardized For 70% Polyphenols, 50% Catechins, 25% EGCG), Theobroma Cacao Extract (Seed) (Standardized 
For 6% Theobromine), White Tea Extract (As Camellia Sinensis)(Leaf) (Standardized For 50% Polyphenols, 35% 
Catechins, 15% EGCG), White Willow Extract (As Salix Alba)(Bark) (Standardized For 25% Salicin) 
N-Acetyl-L-Tyrosine, L-Tyrosine, Sulbutiamine, Vinpocetine, Alpha Glycerophosphocholine, Cis-9, 10-
Octadecenoamide, Huperzine-A (As Huperzia Serrata) 
Quercetin Dihydrate, Dihydroxy-Diosgenin (25R-5 Alpha-Spirostan-2-Alpha, 3-Beta), N-Acetyl L-Cysteine, N-
Acetyl-5-Methoxytryptamine 
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was most sensitive when the sensor was applied to the
anterior deltoid muscle (as opposed to the pectoralis
major or pectoralis minor muscle).
NIRS is widely used around the world for monitoring
tissue oxygen saturation in trauma and critical care medi-
cine; however, it has only been used in a few exercise
related studies [19-21], and may have some limitations
compared to a more sophisticated tool such as magnetic
resonance imaging [22]. Moreover, it should be under-
s t o o d  t h a t  t h i s  d e v i c e  i s  n o t  d i r e c t l y  m e a s u r i n g  b l o o d
flow in the same manner as using flow mediated dilation
via ultrasound technology. Our rationale for using this
instrument in the present design was that if the condi-
tions actually promoted an increase in blood flow (via any
mechanism), then the amount of oxygen saturation at the
start of each set of exercise may be greater and the per-
cent of desaturation may be less at the conclusion of each
set of exercise. Based on this rationale, we recorded the
precise starting oxygen saturation (StO2 start) and ending
oxygen saturation (StO2 end) for each of the 10 sets of
exercise. The difference was also calculated for each set.
It has been suggested that carnitine supplementation
may improve blood flow regulation and the delivery of
oxygen to muscle tissue during and after exercise [23].
S u c h  a n  i n c r e a s e  i n  o x y g e n  d e l i v e ry  m a y  d e c r e a s e  t h e
degree of tissue ischemia and subsequent free radical for-
mation, leading to less oxidation of cellular lipids and
other macromolecules [24]. Likewise, although not yet
supported by the scientific literature, it is suggested in lay
press publications that an increase in oxygen delivery to
muscle tissue during exercise will improve physical per-
formance. The collective measures employed in the pres-
ent study address these issues.
Blood Collection and Biochemistry
At two times (pre-intake of condition and fasting; within
one minute following the completion of set 10 of bench
press exercise) blood was collected (~7mL) from subjects'
antecubital veins using a needle and collection tube. Sin-
gle samples were immediately analyzed for whole-blood
lactate using an Accutrend portable lactate analyzer
(Roche Diagnostics, Mannheim, Germany). The remain-
der of whole blood was immediately processed for plasma
and stored at -70°C until analysis within three months of
collection. The following assays for nitrate/nitrite and
malondialdehyde were performed in duplicate.
Nitrate/nitrite was analyzed in plasma using a commer-
cially available colorimetric assay kit (Catalog#: 780001;
Caymen Chemical, Ann Arbor, MI), according to the pro-
cedures provided by the manufacturer. After being
thawed, plasma samples were centrifuged at 10,000xg for
5 minutes in a refrigerated centrifuge (4°C). Following the
addition of a nitrate reductase co-factor to each diluted
sample, nitrate reductase was added and the mixture was
incubated for three hours to allow for the full conversion
of nitrate to nitrite. Greiss reagent was then added, which
converts nitrite into a deep purple azo compound. The
absorbance was then detected photometrically at 540nm.
Quantification was performed with a calibration curve.
The coefficient of variation for this assay in our labora-
tory is <8%. The detection limit, as per the manufacturer,
is ≥2.5 μM.
Malondialdehyde was analyzed in plasma following the
procedures of Jentzsch et al. [25] using reagents pur-
chased from Northwest Life Science Specialties (Vancou-
ver, WA). Specifically, 75 μL of plasma was added to
microcentrifuge reaction tubes with the addition of 3 μL
of butylated hydroxytoluene in methanol to minimize ex
vivo lipid peroxidation. 75 μL of 1M phosphoric acid and
75 μL of 2-thiobarbituric acid reagent was added to each
reaction tube and mixed thoroughly. Samples and
reagents were incubated for 60 minutes at 60°C. Follow-
ing incubation, tubes were removed and the reaction
mixture was transferred to a microplate and the absor-
bance read using a spectrophotometer at both 535 and
572nm to correct for baseline absorption. Malondialde-
hyde equivalents were calculated using the difference in
absorption at the two wavelengths. Quantification was
performed with a calibration curve using tetramethoxy-
propane in a stabilizing buffer. The coefficient of varia-
tion for this assay in our laboratory is <6%. The detection
limit, as per the manufacturer, is 0.1 μM.
Physical Activity and Dietary Intake
Subjects were asked to refrain from strenuous physical
activity during the 48 hours before test days. Subjects
were asked to record all food and drink consumed during
the 24 hours prior to each test day. Upon receipt of the
first 24 hour diet record, subjects received a copy and
were asked to duplicate this intake during the 24 hour
period immediately prior to all subsequent test days.
However, to verify that subjects consumed similar
intakes, they recorded food and drink for the 24 hours
prior to each test day and all records were analyzed for
total calories, protein, carbohydrate, fat, vitamin C, vita-
min E, and vitamin A (Food Processor SQL, version 9.9,
ESHA Research, Salem, OR).
Statistical Analysis
All performance data, mean HR, mean RPE, and dietary
data were analyzed using an analysis of variance
(ANOVA). Blood HLa, NOx, MDA, subjective muscle
pump, and circumference data were analyzed using a 5
(condition) × 2 (time) ANOVA. The StO2 data (start, end,
difference) were first analyzed using a 5 (condition) × 10
(set number) ANOVA. The data were then collapsed by
set number and simply analyzed using an ANOVA in
order to compare conditions without considering setBloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
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number. Post hoc testing was performed using the proce-
dures of Tukey. The outcome data are presented as mean
± standard error of the mean. Subject descriptive charac-
teristics are presented as mean ± standard deviation. All
analyses were performed using JMP statistical software
(version 4.0.3, SAS Institute, Cary, NC). Statistical signifi-
cance was set at P ≤ 0.05.
Results
Dietary Intake
Dietary data did not differ between conditions for total
kilocalories (p = 0.83), protein (p = 0.99), carbohydrate (p
= 0.84), fat (p = 0.43), vitamin C (p = 0.91), vitamin E (p =
0.58), or vitamin A (p = 0.41). Data are presented in Table
2.
Performance Measures
No statistically significant differences were noted
between conditions for bench press power (p = 0.93), reps
performed during the first set (p = 0.99), total reps per-
formed (p = 0.98), mean reps performed (p = 0.98), total
volume load (p = 0.99), mean volume load (p = 0.99),
mean heart rate over the 10 sets (p = 0.56), or mean per-
ceived exertion over the 10 sets (p = 0.98). Although not
statistically significant, the following are noted: SUPP1
resulted in the greatest power output during the bench
press throws, with values higher than the placebo (5.8%),
GlycoCarn®  (2.5%), SUPP2 (0.4%), and SUPP3 (1.5%).
Likewise, GlycoCarn® resulted in the greatest total volume
load during the 10 set protocol, with values higher than
the placebo (3.3%), SUPP1 (4.2%), SUPP2 (2.5%), and
SUPP3 (4.6%). Mean HR was highest with SUPP2, with
values higher than the placebo (8.4%), GlycoCarn® (5.2%),
SUPP1 (6.0%), and SUPP3 (3.6%). Other variables were
essentially the same between conditions. Data are pre-
sented in Table 3.
Muscle Tissue Oxygen Saturation
When considering the condition × set number ANOVA,
the following was noted: For StO2 at the start of exercise,
no condition × set number interaction was noted (p =
1.00). A condition effect was noted (p = 0.02), with Glyco-
Carn® higher than SUPP2 (p < 0.05). A time effect was also
noted (p < 0.0001), with set number one lower than all
other sets (p < 0.05). For StO2 at the end of exercise, no
condition × set number interaction was noted (p = 1.00).
A condition effect was noted (p = 0.003), with SUPP1
lower than all other conditions (p < 0.05). A time effect
was also noted (p = 0.002), with set number one lower
than sets 5-10 (p < 0.05). For StO2 difference (start-end),
no condition × set number interaction was noted (p =
1.00). A condition effect was noted (p = 0.004), with
SUPP1 greater than all other conditions (p < 0.05). No
time effect was noted (p = 0.94). Data are presented in
Table 4.
When removing set number from the model and only
considering the condition comparison, an effect was
noted for StO2 at the end of exercise (p = 0.003), with
SUPP1 lower than all other conditions. An effect was also
noted for StO2 difference (p = 0.003), with SUPP1 greater
than all other conditions. No statistically significant dif-
ference was noted between conditions for StO2 at the
start of exercise (p = 0.12). Data are presented in Table 5.
Muscle Pump
No statistically significant interaction (p = 0.80) or condi-
tion effect (p = 0.74) was noted for subjective muscle
pump. However, a time main effect was noted (p <
Table 2: Dietary data of 19 resistance trained men receiving placebo or supplement in a cross-over design.
Variable Baseline Placebo GlycoCarn® SUPP1 SUPP2 SUPP3
Kilocalories 2352 ± 212 2592 ± 216 2881 ± 245 2617 ± 222 2915 ± 272 2795 ± 248
Protein 
(grams)
127 ± 19 140 ± 19 138 ± 18 134 ± 21 138 ± 18 137 ± 17
Carbohydrate 
(grams)
288 ± 31 295 ± 33 353 ± 38 335 ± 38 334 ± 37 320 ± 33
Fat (grams) 79 ± 9 98 ± 13 105 ± 13 86 ± 9 119 ± 14 107 ± 13
Vitamin C (mg) 102 ± 25 68 ± 16 88 ± 15 85 ± 30 68 ± 18 85 ± 17
Vitamin E (mg) 6 ± 2 5 ± 1 6 ± 1 7 ± 2 9 ± 2 7 ± 2
Vitamin A (RE) 516 ± 138 303 ± 76 584 ± 148 511 ± 130 371 ± 79 588 ± 174
Data are mean ± SEM.
No statistically significant difference noted between conditions for kilocalories (p = 0.83), protein (p = 0.99), carbohydrate (p = 0.84), fat (p = 
0.43), vitamin C (p = 0.91), vitamin E (p = 0.58), or vitamin A (p = 0.41).
Values are for the 24 hour period immediately preceding each test condition.Bloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
http://www.jissn.com/content/7/1/16
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0.0001), with values higher post-exercise compared to
pre-exercise. No statistically significant interaction (p =
0.99), condition (p = 0.99), or time effect (p = 0.34) was
noted for the circumference measure. Data are presented
in Table 6.
Biochemical Measures
No statistically significant interaction (p = 0.22) or condi-
tion effect (p = 0.20) was noted for HLa. However, a time
main effect was noted (p < 0.0001), with values higher
post-exercise compared to pre-exercise. No statistically
significant interaction (p = 0.98), condition (p = 0.31), or
time effect (p = 0.77) was noted for NOx. No statistically
significant interaction (p = 0.45), condition (p = 0.33), or
time effect (p = 0.19) was noted for MDA. However,
MDA decreased 13.7% from pre-exercise to post-exercise
with GlycoCarn® and increased in placebo (9.3%), SUPP1
(37.9%), SUPP2 (1.2%), and SUPP3 (20.0%). Data are pre-
sented in Table 7.
Discussion
Our findings indicate that, compared to a maltodextrin
placebo, none of the products tested in the present study
result in effects that are statistically different with regards
to exercise performance, skeletal muscle blood flow, mus-
cle pump, HLa, NOx, or MDA. These findings clearly
refute the advertisement claims for these products, at
least in the context of their use to impact acute exercise
performance, blood flow, muscle pump, and NOx within
a controlled laboratory environment. Of course, it is pos-
sible that 1) routine use of these products may result in
favorable effects in our chosen variables over time (this is
especially true for such ingredients as creatine and beta
alanine) and/or 2) the products may influence variables
that were not measured within the present design (e.g.,
those influencing exercise recovery; lower body exercise
performance; exercise performance assessed at a higher
relative intensity). Additional study would be needed to
generate such data.
It is interesting to note that the single ingredient Glyco-
Carn® (in addition to 16 grams of maltodextrin as used in
the present design) results in similar or more-favorable
effects in terms of blood flow (StO2 start of exercise; as
measured by NIRS), as well as the total volume load mea-
sured during the 10 set bench press protocol. Although
not of statistical significance, from a practical standpoint,
the percent increases in volume load above placebo and
the other supplements may be of importance to serious
athletes desiring a slight performance advantage. More-
over, while a slight to moderate increase in lipid specific
oxidative stress (as measured by MDA) was observed
with all other conditions, the noted decrease with Glyco-
Carn® may be of interest to those seeking antioxidant sup-
port within a pre-workout dietary supplement.
Admittedly, the importance of these subtle differences in
blood flow, total volume load, and MDA in relation to
exercise performance and recovery are unknown at the
present time and require additional study. Hence, athletes
will need to consider the cost to benefit ratio when mak-
ing such a decision as to whether or not to use an ingredi-
ent such as GlycoCarn®.
Table 3: Exercise performance data of 19 resistance trained men receiving placebo or supplement in a cross-over design.
Variable Baseline Placebo GlycoCarn® SUPP1 SUPP2 SUPP3
Bench press 
power (W)
1029 ± 51 1019 ± 47 1052 ± 50 1078 ± 53 1073 ± 49 1062 ± 52
Reps 1st set 25 ± 1 25 ± 1 26 ± 1 26 ± 1 26 ± 1 26 ± 1
Total reps 101 ± 6 105 ± 7 109 ± 6 104 ± 6 106 ± 5 104 ± 6
Mean reps 10.1 ± 0.6 10.5 ± 0.7 10.9 ± 0.6 10.4 ± 0.6 10.6 ± 0.5 10.4 ± 0.6
Total volume 
load (kg)
7221 ± 550 7495 ± 545 7746 ± 528 7432 ± 559 7558 ± 513 7407 ± 499
Mean volume 
load (kg)
722.1 ± 55.0 749.5 ± 54.5 774.6 ± 52.8 743.2 ± 55.9 755.8 ± 51.3 740.7 ± 49.9
Heart rate* 
(bpm)




14.7 ± 0.6 14.8 ± 0.4 14.7 ± 0.4 14.8 ± 0.4 14.6 ± 0.4 14.8 ± 0.4
Data are mean ± SEM.
No statistically significant difference noted between conditions for bench press power (p = 0.93), reps 1st set (p = 0.99), total reps (p = 0.98), 
mean reps (p = 0.98), total volume load (p = 0.99), mean volume load (p = 0.99), heart rate (p = 0.56), or perceived exertion (p = 0.98).
*Heart rate and perceived exertion recorded at the end of each of the 10 sets of bench press exercise. Mean data presented in table.Bloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
http://www.jissn.com/content/7/1/16
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Table 4: Muscle tissue oxygen saturation data for 10 sets of bench press exercise in 19 resistance trained men receiving 
placebo or supplement in a cross-over design.
Variable†
Condition
S e t  1 * * S e t  2S e t  3S e t  4S e t  5S e t  6S e t  7S e t  8S e t  9 S e t  1 0
StO2 start (%) 
Baseline
85.2 ± 1.1 90.2 ± 1.3 91.0 ± 1.0 91.2 ± 1.1 91.4 ± 0.9 91.8 ± 0.9 91.9 ± 0.8 92.2 ± 0.8 92.1 ± 0.8 92.7 ± 0.7
StO2 end (%) 
Baseline




45.5 ± 3.3 45.4 ± 3.4 43.7 ± 3.9 43.9 ± 3.5 42.4 ± 2.8 42.1 ± 2.8 41.8 ± 2.6 44.4 ± 2.9 44.1 ± 2.7 44.7 ± 3.3
StO2 start (%) 
Placebo
84.3 ± 1.3 91.0 ± 0.8 91.4 ± 0.8 91.8 ± 0.7 91.9 ± 0.8 92.3 ± 0.7 92.0 ± 0.7 92.2 ± 0.7 92.5 ± 0.6 92.5 ± 0.6
StO2 end (%) 
Placebo




45.1 ± 3.5 45.2 ± 4.3 42.5 ± 4.2 43.0 ± 4.6 41.2 ± 3.8 43.3 ± 4.3 42.9 ± 4.1 44.3 ± 4.0 42.5 ± 4.1 42.3 ± 3.9
StO2 start (%) 
GlycoCarn®*
84.5 ± 0.8 92.1 ± 0.5 92.5 ± 0.5 92.5 ± 0.4 93.0 ± 0.4 92.9 ± 0.4 93.1 ± 0.5 92.9 ± 0.4 93.0 ± 0.4 92.7 ± 0.5
StO2 end (%) 
GlycoCarn®




44.0 ± 3.7 46.8 ± 3.4 45.6 ± 4.6 43.5 ± 3.8 41.1 ± 3.7 41.4 ± 3.7 42.6 ± 3.7 40.4 ± 3.6 43.3 ± 3.9 42.4 ± 3.4
StO2 start (%) 
SUPP1
83.6 ± 1.1 90.7 ± 0.8 91.3 ± 0.7 91.6 ± 0.6 91.8 ± 0.7 92.1 ± 0.6 92.7 ± 0.5 92.5 ± 0.6 92.4 ± 0.5 92.4 ± 0.5
StO2 end (%) 
SUPP1***




45.2 ± 4.8 50.4 ± 4.9 50.6 ± 4.7 48.4 ± 4.7 48.9 ± 4.5 48.1 ± 4.3 46.5 ± 4.6 49.4 ± 4.6 48.5 ± 4.7 47.1 ± 4.8
StO2 start (%) 
SUPP2*
85.7 ± 1.3 90.1 ± 0.9 90.6 ± 0.8 91.4 ± 0.7 91.7 ± 0.7 91.6 ± 0.7 91.9 ± 0.7 92.5 ± 0.7 91.9 ± 0.7 92.5 ± 0.7
StO2 end (%) 
SUPP2




47.5 ± 3.3 45.8 ± 3.8 43.4 ± 3.9 43.9 ± 3.4 41.7 ± 3.5 42.1 ± 4.1 40.9 ± 3.8 42.1 ± 4.0 40.8 ± 3.6 38.9 ± 3.4
StO2 start (%) 
SUPP3
84.2 ± 1.1 90.8 ± 0.9 91.1 ± 0.9 91.6 ± 0.8 91.7 ± 0.7 91.9 ± 0.7 92.0 ± 0.6 92.1 ± 0.6 92.4 ± 0.6 92.9 ± 0.6
StO2 end (%) 
SUPP3
42.9 ± 4.2 47.1 ± 4.1 47.9 ± 3.7 50.9 ± 4.0 47.9 ± 3.3 49.7 ± 3.6 49.5 ± 3.9 51.3 ± 3.9 51.0 ± 4.0 51.1 ± 4.0Bloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
http://www.jissn.com/content/7/1/16
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While several anecdotal reports exist indicating a per-
formance benefit when using the products tested in the
current study, we are unaware of any peer reviewed scien-
tific manuscripts that examine any of these products.
Based on the caffeine and other supposed performance
aids contained within these products, we believed that it
would be possible that a performance effect would be
observed. However, because the actual dosage of ingredi-
ents contained within the products is unknown within a
proprietary blend (see Figures 1, 2, and 3), it is possible
that the actual amount of caffeine and other ingredients is
simply too low to promote an ergogenic effect. In fact,
studies using caffeine to improve resistance exercise per-
formance have been mixed, as noted in a recent compre-
hensive review [3]. One recent study found no effect of a
caffeine containing dietary supplement on resistance
exercise performance, despite using a relatively high dos-
age of caffeine (400mg) [26]. Even this amount, which
may not be adequate for many individuals, would corre-
late to approximately 5mg•kg-1 for subjects in the present
study (based on a mean body mass of 80kg). Although not
possible to determine from looking at the product labels,
based on the lack of a performance effect, it is doubtful
that the caffeine dosage contained within the tested prod-
ucts is adequate.
Aside from caffeine (and agents such as creatine and
beta alanine--which need to be consumed on a regular
basis in order to provide ergogenic effects), the tested
products contain very few additional ingredients that
have been shown in human clinical research studies to
provide an ergogenic effect. Moreover, as with caffeine,
the dosage of each specific ingredient may be too low to
provide any benefit. Logic dictates that if a single serving
has a weight of 20 grams and half of the serving is com-
prised of carbohydrate and flavoring, little weight
remains for each of the additional 30-60 ingredients. Our
data clearly show that ingredient number has no influ-
ence on product effectiveness. In fact, the use of a very
inexpensive maltodextrin powder yields similar effects as
all products used for comparison in this design. Consid-
ering a per-serving cost of approximately $2 (when using
the amount of powder included within the present
design), the reasonable choice for an athlete may simply
be to use a carbohydrate powder. That being said, it
should be reiterated that the tested products may provide
benefit outside of the measures tested in the present
design, and because of this, they may in fact be superior
to maltodextrin with regards to other measures (as well as
our included measures, albeit tested using a different
study design). This important issue should be considered
by athletes and sport nutritionists when making such a
decision.
Pertaining to ingredients, the amino acid L-arginine is a
component of all three supplements used in the present
study, as well as most other "nitric oxide stimulating"
dietary supplements sold on the market today. While L-
arginine is indeed the precursor to nitric oxide biosynthe-
sis and has been associated with enhanced vasodilatation
[27,28], the rationale for inclusion of L-arginine within
pre-workout supplements is primarily based on research
using intravenous L-arginine, often at dosages as high as
20-30 grams, and not oral intake of L-arginine at a dosage
of 3-5 grams. Studies comparing intravenous and oral L-
arginine indicate no effect of oral L-arginine on vasodila-
tation, possibly due to variance in oral L-arginine bio-
availability [29]. Additionally, studies involving oral
intake of L-arginine at dosages from 10-20 grams indicate
no benefit with regards to increasing nitric oxide or
enhancing blood flow [30-32].
A further problem with the use of L-arginine as a nitric
oxide stimulator is that L-arginine availability is likely not
the rate limiting component in this reaction. Rather,
nitric oxide synthase enzymes appear most important
[33]. Two recent investigations provide support for this
point. In one study , 3 grams per day of L-arginine was




41.2 ± 3.8 43.7 ± 3.9 43.2 ± 3.5 40.7 ± 3.7 43.8 ± 3.2 42.2 ± 3.4 42.6 ± 3.7 40.8 ± 3.7 41.4 ± 3.8 41.8 ± 3.7
Data are mean ± SEM.
StO2 Start: *Condition effect (p = 0.02); GlycoCarn® higher than SUPP2. **Time effect (p < 0.0001); Set 1 lower than all other sets. No condition × 
set interaction (p = 1.00).
StO2 End: ***Condition effect (p = 0.003); SUPP1 lower than all other conditions. **Time effect (p = 0.002); Set 1 lower than sets 5-10. No condition 
× set interaction (p = 1.00).
StO2 Difference: ***Condition effect (p = 0.004); SUPP1 greater than all other conditions. No time effect (p = 0.94) or condition × set interaction 
(p = 1.00).
† StO2 values monitored continuously during the 10 set exercise protocol. Start values indicate the value prior to beginning each set of exercise. 
End values indicate the value at the conclusion of each set of exercise.
Table 4: Muscle tissue oxygen saturation data for 10 sets of bench press exercise in 19 resistance trained men receiving 
placebo or supplement in a cross-over design. (Continued)Bloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
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but rather reduced exercise time to fatigue in patients
with peripheral arterial disease [34]. Another study
involved supplementation with 6 grams per day of L-argi-
nine in exercise trained men, and noted no effect on
nitric oxide production, lactate and ammonia metabo-
lism, or performance in intermittent anaerobic exercise
[35]. Based on the above, adding L-arginine to a pre-
workout powder for purposes of increasing nitric oxide is
not supported by the available literature.
One final consideration is the knowledge that while
brief production of nitric oxide at low (nanomolar) con-
centrations favor enhanced blood flow, high concentra-
tions favor cell cycle arrest and apoptosis. Moreover, it is
important to keep in mind that high levels of nitric oxide
can react with superoxide anion to form peroxynitrite, a
very harmful chemical [36] involved in nitrosative stress
[37]. Therefore, dramatically increasing nitric oxide via
use of nutritional supplements, assuming this is actually
possible, does not appear desirable. Considering the find-
ings presented here indicating a lack of increase in
nitrate/nitrite, none of the tested supplements would be
thought to promote an increase in peroxynitrite.
A few previous studies have used the measure of NIRS
to assess tissue blood flow during resistance exercise [19-
21]. Our findings are similar to those previously pre-
sented, indicating a significant decrease in StO2 from the
start to the end of the exercise set, with a return to pre-set
values within one minute of exercise recovery (data not
shown). W e also show here that as an exercise session
continues, blood flow to the muscle is increased, as evi-
denced by the increase in StO2 at the start of exercise
from set one to set two and beyond (Table 4). However,
despite popular writings within fitness and bodybuilding
publications indicating that nitric oxide controls skeletal
muscle blood flow during exercise, scientific evidence
refutes this notion, demonstrating that nitric oxide plays
o n l y  a  n o n - o b l i g a t o r y  r o l e  i n  e x e r c i s e  h y p e r e m i a  [ 3 8 ] .
Our data support this notion, in that blood flow as mea-
sured using StO2 (start of exercise) increased approxi-
mately 10% from set one to set 10, despite the finding that
NOx remained essentially unchanged from pre- to post-
exercise (Table 7). As an aside, we believe that the inclu-
sion of NIRS allows for the accurate measure of muscle
tissue oxygen saturation, with very little error. This device
may have value in future experiments designed to
approximate muscle tissue blood flow with and without
the use of dietary supplements.
I n  r e l a t i o n  t o  m u s c l e  b l o o d  f l o w ,  m a n y  a n e c d o t a l
reports indicate a more robust muscle pump when using
pre-workout products designed to increase nitric oxide.
Our data using a subjective rating scale for muscle pump,
in addition to circumference measures, indicate that no
such effect is observed in a controlled laboratory environ-
ment. In this regard, a placebo effect is certainly possible
[39], leading individuals to believe that such an effect is
absolute; as many individuals using such products are
inundated with advertisements claiming increased blood
flow and muscle pump. At the present time, these claims
remain unsubstantiated. This phenomenon is described
in detail within a recent review of nitric oxide dietary
supplements for sports [2]. Admittedly, our measures of
muscle pump, although performed to the best of our
known abilities, are rather crude. Perhaps if a more
sophisticated measure were available to assess muscle
pump, we may have noted condition differences. How-
ever, even if this were the case, the main findings of no
difference in performance measures may overshadow any
potential effects for muscle pump.
Table 5: Muscle tissue oxygen saturation data pooled over 10 sets of bench press exercise in 19 resistance trained men 
receiving placebo or supplement in a cross-over design.
Variable† Baseline Placebo GlycoCarn®  SUPP1 SUPP2 SUPP3
StO2 start of 
exercise (%)
90.9 ± 0.3 91.2 ± 0.3 91.9 ± 0.2 91.1 ± 0.3 91.0 ± 0.3 91.1 ± 0.3
StO2 end of 
exercise* (%)




43.8 ± 1.0 43.2 ± 1.3 43.3 ± 1.2 48.3 ± 1.4 42.7 ± 1.1 42.1 ± 1.1
Data are mean ± SEM.
*Condition effect for StO2 end of exercise (p = 0.003); SUPP1 lower than all other conditions.
*Condition effect for StO2 difference (p = 0.003); SUPP1 greater than all other conditions.
No statistically significant difference noted between conditions for StO2 start of exercise (p = 0.12).
† StO2 values monitored continuously during the 10 set exercise protocol. Start values indicate the value prior to beginning each set of 
exercise. End values indicate the value at the conclusion of each set of exercise. The mean value of the 10 sets for each subject, under each 
condition, was used in data analysis.Bloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
http://www.jissn.com/content/7/1/16
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Our findings for no change in NOx with GlycoCarn ®
refute our initial work, in which we have noted an
increase in both resting [14] and stress-induced NOx
[13]. The discrepancies in findings may be due to the fact
that in the present design we simply provide a single serv-
ing of GlycoCarn® prior to exercise, whereas our prior
work involved four [13] or eight [14] weeks of GlycoCarn®
treatment. Likewise, our data are in opposition to the
work of Jacobs and colleagues [12] who recently reported
an improvement of 2.6-15% in high intensity cycle sprint
performance with 4.5 grams of GlycoCarn® compared to a
placebo. In this same study these investigators also noted
an approximate 16% decrease in post-exercise blood HLa
with GlycoCarn® compared to placebo. Differences in the
exercise protocol likely contributed to the discrepancy in
findings between the two studies. Finally, we have noted
previously that GlycoCarn® results in lower resting MDA
following chronic intake [14]. The present study extends
those findings by noting a decrease, albeit statistically
insignificant, in MDA from pre- to post-exercise, indicat-
ing a potential antioxidant effect. Interesting to note, this
favorable effect of GlycoCarn® on MDA reduction was
associated with the highest StO2 at the start of exercise,
indicating a possible association between increased blood
flow and decreased lipid peroxidation. The converse was
also true, as SUPP1 demonstrated the greatest increase in
MDA from pre- to post-exercise, while displaying the
lowest StO2 at the start of exercise and the greatest drop
in StO2 from the start to the end of exercise. These find-
ings support the idea that exercise-induced hypoxia is
associated with increased lipid peroxidation, likely due to
increased free radical production [24].
It is possible that chronic treatment of GlycoCarn® may
result in more robust changes in MDA or other markers
of oxidative stress. Using a different stress protocol
(handgrip dynamometry vs. resistance exercise), we have
r e p o r t e d  r e c e n t l y  t h a t  f o u r  w e e k s  o f  G l y c o C a r n ® treat-
ment at a daily dosage of 4.5 grams in resistance trained
men results in a 45% decrease in oxidized to total gluta-
thione ratio [40]. Additional work is needed to determine
the antioxidant effect of chronic GlycoCarn® administra-
tion following resistance exercise, and to determine
whether or not such an effect translates into improved
post-exercise recovery.
One explanation for our lack of a performance effect for
the chosen supplements, in addition to GlycoCarn®, could
be our specific sample of subjects. That is, they may have
been non-responders to treatment, as has been reported






Baseline Pre 101.6 ± 1.3 1.4 ± 0.3
Baseline Post 102.5 ± 1.3 7.8 ± 0.2
Placebo Pre 101.9 ± 1.0 1.2 ± 0.1
Placebo Post 102.2 ± 1.1 7.5 ± 0.3
GlycoCarn® Pre 101.3 ± 1.1 1.3 ± 0.1
GlycoCarn® Post 102.4 ± 1.1 7.7 ± 0.3
SUPP1 Pre 101.3 ± 1.1 1.4 ± 0.2
SUPP1 Post 101.6 ± 1.1 7.9 ± 0.2
SUPP2 Pre 101.7 ± 1.2 1.2 ± 0.1
SUPP2 Post 102.2 ± 1.1 8.0 ± 0.3
SUPP3 Pre 101.2 ± 1.1 1.3 ± 0.1
SUPP3 Post 102.2 ± 1.1 7.7 ± 0.3
Data are mean ± SEM.
No statistically significant interactions or condition effects noted for either variable (p > 0.05).
* Time main effect for perceived muscle pump (p < 0.0001).
Pre = before exercise; Post = after exerciseBloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
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previously for a variety of sport supplements including
caffeine [41], creatine [42], and GlycoCarn®, in terms of
nitrate/nitrite [13]. If this were true, it is possible that a
different group of subjects may have responded positively
to treatment. This should be considered when athletes
are contemplating the use of such products. For example,
of our 19 subjects, 11 responded positively to GlycoCarn®
in terms of total volume load, with a mean improvement
above placebo of 12.6%. This is in opposition to the 3.3%
improvement above placebo when including all 19 sub-
jects in the analysis. Of course, serial studies are needed
to note the number of individuals who consistently and
reliably respond to treatment. As with most nutritional
supplements, the simple reality is that some individuals
will likely respond well to treatment (i.e., experience a
noted improvement in performance and/or some other
variable of interest), while others will likely experience no
benefit. In this case, individual experimentation is
needed.
Conclusion
We conclude that when compared to a maltodextrin pla-
cebo, none of the products tested in the present study
resulted in effects that are statistically different with
regards to exercise performance, skeletal muscle blood
flow, muscle pump, HLa, NOx, or MDA. The single
ingredient GlycoCarn®  (combined with 16 grams of
maltodextrin) resulted in the highest StO2 at the start of
exercise and a reduction in exercise-induced lipid peroxi-
dation, as measured by plasma MDA. Although not of
statistical significance, SUPP1 resulted in a greatest
power output during the bench press throws compared to
the placebo and other conditions (range: 0.4%-5.8%), and
GlycoCarn® resulted in a greater total volume load com-
pared to the placebo and the supplements tested (range:
2.5%-4.6%). These data indicate that 1) a single ingredient
(GlycoCarn®) can provide similar practical benefit as
compared to finished products containing multiple ingre-
dients pertaining to many of the outcome measures
included within the present design, and 2) the tested fin-
ished products are clearly ineffective in terms of increas-
ing blood flow and improving acute upper body exercise
performance, and do not produce results that match the
widely advertised marketing claims. These concluding
statements should be considered within the context of the
current study design, and may not be generalized to other
designs inclusive of different exercise modes and intensi-
ties, and/or different outcome measures.







Baseline Pre 1.85 ± 0.12 22.18 ± 2.43 0.71 ± 0.06
Baseline Post 5.97 ± 0.33 22.11 ± 2.43 0.76 ± 0.09
Placebo Pre 2.03 ± 0.22 17.74 ± 1.57 0.75 ± 0.08
Placebo Post 6.52 ± 0.34 19.90 ± 1.67 0.82 ± 0.10
GlycoCarn® Pre 1.81 ± 0.13 22.72 ± 3.39 0.73 ± 0.06
GlycoCarn® Post 6.62 ± 0.41 21.68 ± 2.39 0.63 ± 0.04
SUPP1 Pre 2.08 ± 0.14 23.61 ± 3.46 0.58 ± 0.07
SUPP1 Post 7.51 ± 0.43 23.57 ± 3.21 0.80 ± 0.11
SUPP2 Pre 1.89 ± 0.16 18.89 ± 2.29 0.80 ± 0.12
SUPP2 Post 7.20 ± 0.37 19.89 ± 2.25 0.81 ± 0.11
SUPP3 Pre 1.53 ± 0.12 21.92 ± 2.91 0.66 ± 0.08
SUPP3 Post 7.10 ± 0.31 22.33 ± 2.69 0.79 ± 0.08
Data are mean ± SEM.
No statistically significant interactions or condition effects noted for any variable (p > 0.05).
* Time main effect for lactate (p < 0.0001).
Pre = before exercise; Post = after exerciseBloomer et al. Journal of the International Society of Sports Nutrition 2010, 7:16
http://www.jissn.com/content/7/1/16
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